Vid Stanulović
Sanofi (France)(FR)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Monoclonal and Polyclonal Antibodies Research, Pharmaceutical studies and practices, Diabetes, Cardiovascular Risks, and Lipoproteins, Mosquito-borne diseases and control
Most-Cited Works
- → Drug rechallenge following drug‐induced liver injury(2017)74 cited
- → Monoclonal Antibodies as Neurological Therapeutics(2021)56 cited
- → Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies(2021)45 cited
- → Atrio-ventricular block as the first presentation of disseminated Lyme disease(2010)10 cited
- → Intentional Rechallenge: Does the Benefit Outweigh the Risk?(2013)8 cited
- → Predictability of serious adverse reaction alerts for monoclonal antibodies(2011)4 cited
- → Doing damage by being over-cautious?(2009)3 cited
- → Impact of causal uncertainty on rechallenge after dress syndrome has occurred(2019)1 cited
- → Overview of Adverse Reactions of Radiopharmaceuticals(2025)
- → Clinical trials of statins and fibrates: A meta-analysis(2006)